Evidence Summary
- Evidence Level
- Moderate
- Mechanism
- Enrollment: Actual, Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Fed
- Safety
- Bradycardia, visual phosphenes (luminous phenomena), headache. Contraindicated in sick sinus, severe hypotension, acute decompensated HF. Monitor HR.
- Dosing
- 2.5–7.5 mg twice daily; titrate to HR; durations in POTS/autonomic studies 4–12 weeks or longer.
Observational success ~55% + nested COVIVA RCT. Selective HR reduction without beta effects. 2.5-7.5mg BID. Visual side effects possible. Strong for hyperadrenergic POTS/IST phenotypes.
Clinical Trials
2 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT06305806 | RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) | Phase 2 | Completed |
| NCT05481177 | Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort | Phase 4 | Unknown status |
Key Studies / References
- See linked studies